# Treatment of Familiar Lymphohistiocytosis

> **NCT02472054** · PHASE1,PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 29 (actual)

## Conditions studied

- Hemophagocytic Lymphohistiocytosis (HLH)

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Methyl Prednisolone (MP)
- **DRUG:** Cyclosporin A (CSA)

## Key facts

- **NCT ID:** NCT02472054
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-29
- **Primary completion:** 2019-09-12
- **Final completion:** 2020-05-20
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472054, "Treatment of Familiar Lymphohistiocytosis". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT02472054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*